Acessibilidade / Reportar erro

Optic neuritis due to solvent abuse

Neurite óptica relacionada ao abuso de solvente

CLINICAL / SCIENTIFIC NOTES

Optic neuritis due to solvent abuse

Neurite óptica relacionada ao abuso de solvente

Carlos Alexandre TwardowschyI; Hélio Afonso Ghizoni TeiveII; Fábio SiquineliI; Artur Furlaneto FernandesI; Ismael Paulo BúrigoI; Arnolfo Carvalho-NetoIII; Lineu César WerneckIV

IResident in Neurology - Neurology Service, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná, Curitiba PR, Brazil

IIAdjunt Professor of Neurology - Neurology Service, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná, Curitiba PR, Brazil

IIIAdjunt Professor of Radiology - Neurology Service, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná, Curitiba PR, Brazil

IVFull Professor of Neurology - Neurology Service, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná, Curitiba PR, Brazil

Solvent abuse is a public health problem in Brazil particularly among young adults and children. Inhalation of toluene-based products is popular with solvent sniffers because of the euphoric effect and easy availability of these substances. Chronic inhalation of toluene may result in a variety of neurologic complications like cerebellar dysfunction, optic atrophy, pyramidal tract signs, cranial nerve abnormalities. Also, personality changes, emotional instability and general cognitive decline have been attributed to its abuse1.

We report an unusual case of acute optic neuritis induced by thinner sniffing.

CASE

A 34-year-old man presented with an acute visual loss. He was admitted to the hospital reporting a sudden and progressive loss of visual acuity after sniffing a hole can of thinner during uninterrupted 48 hours. This homeless patient had a history of chronic solvent abuse for five years, moderate alcohol ingestion and tabagism, but denied other substances abuse. At the moment of the admission, 4 days after the beginning of the symptoms, he related to see only countenances. The physical examination and vital data were normal. The neurological examination was normal except for presenting bilateral mydriasis with severe reduction of the photomotor and consensual responses. Visual acuity was worse than 20/200. Ophthalmological examination demonstred bilateral papilledema, with normal ocular pressure and ocular movements. Other cranial nerves were normal. Laboratory examinations are listed in Table. Lumbar puncture showed 130 mmH2O opening pressure, 27 red blood cells/mm³, 1 leucocyte/mm³, glucose concentration 75 mg/dL, protein 39 mg/dL and VDRL was negative. Magnetic resonance imaging (MRI) showed bilateral symmetric hyperintense lesions in the deep white matter, corpus callosum (splenium), centrum semiovale (Fig 1) and pons (Fig 2). EEG was irregular without specific pathological meanings. The patient was treated with methylprednisolone 1 gr/day for three days associated with replacement of B complex vitamins. Six days after the admission, the patient ran away from the hospital and one month later returned in the neurology clinic relating important improvement of the visual acuity.



DISCUSSION

Today, organic solvents contained in industrial and domestic products are the most commonly abused volatile substances. Formerly, benzene was the major organic solvent in paints, lacquers, and thinners. However, benzene is toxic to bone marrow and liver and has been replaced by n-hexane or toluene (methyl benzene), which are neurotoxins. Toluene can cause multifocal neurologic disorders. Prior reports have been concerned with its acute effects1. Because of its lipophilicity, toluene rapidly penetrates into the central nervous system (CNS) after inhalation. Toxic toluene inhalation is most commonly the result of occupational exposure or recreational abuse.

A multiinstitutional study of 138 outpatients and inpatients with solvent dependence reported the organic solvents abused were "thinner" (a word often used as a general term for organic solvents for abuse), 69.6%; pure toluene, 40.6%; and glues, 39%, with multiple replies2.

Gas chromatographic analysis of the volatile solvents revealed that the paint thinner consist almost entirely of toluene (methyl benzene), with traces of xylene (dimethylbenzene). The aerosol products contain 59 to 61% toluene, with traces of xylene and 10% methylene chloride (dichloromethane), a halogenated hydrocarbon. The remainder are propellants (butane-isobutane), which escape as gas when sprayed on the rag and are rarely inhaled. The solvent fractions that are inhaled consisted primarily of toluene and traces of methylene chloride1. Multiple components in the mixtures may enhance the net toxicity in a synergistic or additive fashion. Inhaled volatile hydrocarbons are rapidly absorbed from the lungs. Being highly lipophilic, they most easily enter and are retained within the lipid-rich nervous system.

Toxic and deficiency optic neuropathies are due to toxic chemicals and nutritional deficiency. The visual symptoms (dyschromatopsia and progressive reduction of visual acuity) usually occur bilaterally, simultaneously and painlessly. Total blindness is unusual with the exception of that caused by methanol. Neurologic abnormalities were seen in 65% of patients with a history of chronic solvent vapor abuse for 2 years or more1. The abnormalities were cognitive (60%), pyramidal (50%), cerebellar (45%), cranial nerve brainstem (25%) and tremor (15%).

We found five other reports of optic neuritis induced by thinner sniffing3-6. Like in our case, after they became conscious of their symptoms of slight visual disturbance, they continued to sniffing until they lost their vision. Another similar feature was lack of pain and response to steroids plus vitamin B complex3. The MRI exam did not reveal any signs of optic nerve lesion (Figs 1A, 1B, 2).

The pathogenesis of the MRI lesions in toluene toxicity is poorly understood. Because of its high lipid solubility, toluene accumulates in lipid-rich tissues such as brain. Demyelination and gliosis in the cerebral and cerebellar white matter are the histologic changes reported in chronic toluene abusers7,8.

The cases with diffuse white matter change had a longer duration of abuse and obvious brain atrophy9. All patients with white matter changes had neurologic deficit. The association of white matter changes with abuse longer than 4 years suggests that white matter lesions are the result of a cumulative toxic effect of inhaled toluene8,11.

The main MRI findings in the CNS of the chronic solvent abusers are the white matter change on T2-weighted and proton density-weighted images as the patient reported presents (Figures). This finding is considered to represent the damage in myelin, such as demyelination or myelin pallor, reported in histopathologic reports9.

Periventricular white matter and the centrum semiovale were the most common locations for white matter changes in 19 (46%) of 41 patients, thinning of the corpus callosum was revealed in nine patients (22%), T2-weighted images revealed symmetric hypointensity in the thalami in eight patients (20%). Some investigators have suggested that iron deposition and the partition of toluene into the lipids of cell membranes explain this finding10. T2-weighted images showed restricted white matter changes in 10 (53%) of 19 patients with abnormal MRI imaging findings 11.

Computadorized tomography revealed difuse atrophy of cerebral hemispheres1.

So far, whether diffuse white matter change is caused by the spreading of restricted white matter change is not clear, neither is the reversibility of the white matter change.

Finally, in atypical visual disturbances, several laboratories, neurophysiological and neuroradiological tests are mandatory. Moreover, since pharmacological and nutritional therapies generally only provide a mild degree of symptomatic improvement, further studies are needed in optic neuritis due to solvent abuse.

Received 1 August 2007, received in final form 1 November 2007. Accepted 4 December 2007.

Dr. Carlos Alexandre Twardowschy – Rua Dias da Rocha Filho 261 / 11 - 80040-050 Curitiba PR - Brasil. E-mail: carlos.a.tw@gmail.com

  • 1. Hormes JT, Filley CM, Rosenberg NL. Neurologic sequelae of chronic solvent vapor abuse. Neurology 1986;36:698-702.
  • 2. Fukui S, Wada K, Iyo M. Clinical characteristics of the recent organic solvent dependents who visited psychiatric facilities [in Japanese with English abstract]. J Men Health 1989;35:107-131.
  • 3. Shinya H, Hoshino K, Kiritohshi M, Kiuchi S, Yamagami K, Nakatani T. [2 cases of acute retrobulbar neuritis by thinner inhalation; detected methanol of high concentration in gas phase assay] Chudoku Kenkyu. 2003;16:329-333.
  • 4. Kohriyama K, Hori H, Murai Y, Ninomiya H, Tsukamoto Y. [Optic neuropathy induced by thinner sniffing] J UOEH 1989;11:449-453.
  • 5. Ogawa Y, Takatsuki R, Uema T, et al. Acute optic neuropathy induced by thinner sniffing: inhalation of mixed organic solvent containing methyl alcohol and methyl acetate. Ind Health 1988;26:239-244.
  • 6. Berg EF. Retrobulbar neuritis: a case report of presumed solvent toxicity. Ann Ophthalmol 1971;3:1351.
  • 7. Rosenberg NL, Kleinschmidt BK, Davis KA, Dreisbach JN, Hormes JT, Filley CM. Toluene abuse causes diffuse central nervous system white matter changes. Ann Neurol 1988;23:611-614.
  • 8. Damasceno BP, Capitani EM. Cerebellar atrophy related to chronic exposure to toluene: case report. Arq Neuropsiquiatr 1994:52:90-92.
  • 9. Escobar A, Aruffo C. Chronic thinner intoxication: clinico-pathologic report of a human case. J Neurol Neurosurg Psychiatry 1980;43:986-994.
  • 10 . Yamanouchi N, Okada S, Kodama K, et al. White matter changes caused by chronic solvent abuse. Am J Neuroradiol 1995;16:1643-1649.
  • 11 . Aydin K, Sencer S, Demir T, Ogel K, Tunaci A, Minareci O. Cranial MR findings in chronic toluene abuse by inhalation. Am J Neuroradiol 2002;23:1173-1179.

Publication Dates

  • Publication in this collection
    01 Apr 2008
  • Date of issue
    Mar 2008
Academia Brasileira de Neurologia - ABNEURO R. Vergueiro, 1353 sl.1404 - Ed. Top Towers Offices Torre Norte, 04101-000 São Paulo SP Brazil, Tel.: +55 11 5084-9463 | +55 11 5083-3876 - São Paulo - SP - Brazil
E-mail: revista.arquivos@abneuro.org